Nanoformulated ABT-199 to Effectively Target Bcl-2 at Mitochondrial Membrane Alleviates Airway Inflammation by Inducing Apoptosis

Bao-Ping Tian,Fangyuan Li,Ruiqing Li,Xi Hu,Tian-Wen Lai,Jingxiong Lu,Yun Zhao,Yang Du,Zeyu Liang,Chen Zhu,Wei Shao,Wen Li,Zhi-Hua Chen,Xiaolian Sun,Xiaoyuan Chen,Songmin Ying,Daishun Ling,Huahao Shen
DOI: https://doi.org/10.1016/j.biomaterials.2018.06.020
IF: 14
2019-01-01
Biomaterials
Abstract:Elimination of airway inflammatory cells is essential for asthma control. As Bcl-2 protein is highly expressed on the mitochondrial outer membrane in inflammatory cells, we chose a Bcl-2 inhibitor, ABT-199, which can inhibit airway inflammation and airway hyperresponsiveness by inducing inflammatory cell apoptosis. Herein, we synthesized a pH-sensitive nanoformulated Bcl-2 inhibitor (Nf-ABT-199) that could specifically deliver ABT-199 to the mitochondria of bronchial inflammatory cells. The proof-of-concept study of an inflammatory cell mitochondria-targeted therapy using Nf-ABT-199 was validated in a mouse model of allergic asthma. Nf-ABT-199 was proven to significantly alleviate airway inflammation by effectively inducing eosinophil apoptosis and inhibiting both inflammatory cell infiltration and mucus hypersecretion. In addition, the nanocarrier or Nf-ABT-199 showed no obvious influence on cell viability, airway epithelial barrier and liver function, implying excellent biocompatibility and with non-toxic effect. The nanoformulated Bcl-2 inhibitor Nf-ABT-199 accumulates in the mitochondria of inflammatory cells and efficiently alleviates allergic asthma.
What problem does this paper attempt to address?